PMID- 36265758
OWN - NLM
STAT- MEDLINE
DCOM- 20221125
LR  - 20221226
IS  - 1521-7035 (Electronic)
IS  - 1521-6616 (Linking)
VI  - 245
DP  - 2022 Dec
TI  - mTOR signaling: A pivotal player in Treg cell dysfunction in systemic lupus 
      erythematosus.
PG  - 109153
LID - S1521-6616(22)00234-0 [pii]
LID - 10.1016/j.clim.2022.109153 [doi]
AB  - Systemic lupus erythematosus (SLE) is a typical autoimmune disease characterized 
      by multiorgan involvement and marked variability in clinical presentation. SLE 
      pathogenesis includes regulatory T cell dysfunction and antinuclear antibody 
      production. Mammalian target of rapamycin (mTOR), a serine/threonine kinase in 
      the phosphoinositide 3-kinase (PI3K)-related kinase family, is a therapeutic 
      target for autoimmune diseases such as SLE. Rapamycin, an inhibitor of the mTOR 
      signaling pathway, is a macrolide antibiotic with potent immunosuppressive, 
      antiproliferative and antifibrotic effects. Recently, an increasing number of 
      studies have investigated the role of mTOR in regulatory T (Treg) cells and its 
      impact on SLE pathogenesis. This review aims to systematically summarize the role 
      of the mTOR signaling pathway in SLE pathogenesis, Treg cell dysfunction and SLE 
      treatment.
CI  - Copyright (c) 2022 Elsevier Inc. All rights reserved.
FAU - Zhao, Xingyun
AU  - Zhao X
AD  - Department of Blood Transfusion, The First Affiliated Hospital, Zhejiang 
      University School of Medicine, Hangzhou, China. Electronic address: 
      zhao1112@zju.edu.cn.
FAU - Wang, Shifen
AU  - Wang S
AD  - Department of Blood Transfusion, The First Affiliated Hospital, Zhejiang 
      University School of Medicine, Hangzhou, China. Electronic address: 
      shifenwang@outlook.com.
FAU - Wang, Shengjun
AU  - Wang S
AD  - Department of Laboratory Medicine, The Affiliated People's Hospital, Jiangsu 
      University, Zhenjiang, China; Department of Immunology, Jiangsu Key Laboratory of 
      Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, China. 
      Electronic address: sjwjs@ujs.edu.cn.
FAU - Xie, Jue
AU  - Xie J
AD  - Department of Blood Transfusion, The First Affiliated Hospital, Zhejiang 
      University School of Medicine, Hangzhou, China. Electronic address: 
      zyyyxj2011@zju.edu.cn.
FAU - Cui, Dawei
AU  - Cui D
AD  - Department of Blood Transfusion, The First Affiliated Hospital, Zhejiang 
      University School of Medicine, Hangzhou, China. Electronic address: 
      daweicui@zju.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20221017
PL  - United States
TA  - Clin Immunol
JT  - Clinical immunology (Orlando, Fla.)
JID - 100883537
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
RN  - EC 2.7.1.1 (MTOR protein, human)
SB  - IM
MH  - Humans
MH  - T-Lymphocytes, Regulatory/metabolism
MH  - Phosphatidylinositol 3-Kinases/metabolism
MH  - TOR Serine-Threonine Kinases/metabolism
MH  - *Lupus Erythematosus, Systemic
MH  - Signal Transduction
MH  - Sirolimus/pharmacology
MH  - *Autoimmune Diseases/drug therapy
OTO - NOTNLM
OT  - Autoimmune disease
OT  - Dysfunction
OT  - Regulatory T cells
OT  - Systemic lupus erythematosus
OT  - mTOR
COIS- Declaration of Competing Interest The authors declare that they have no conflicts 
      of interest.
EDAT- 2022/10/21 06:00
MHDA- 2022/11/26 06:00
CRDT- 2022/10/20 19:36
PHST- 2022/07/27 00:00 [received]
PHST- 2022/09/30 00:00 [revised]
PHST- 2022/10/04 00:00 [accepted]
PHST- 2022/10/21 06:00 [pubmed]
PHST- 2022/11/26 06:00 [medline]
PHST- 2022/10/20 19:36 [entrez]
AID - S1521-6616(22)00234-0 [pii]
AID - 10.1016/j.clim.2022.109153 [doi]
PST - ppublish
SO  - Clin Immunol. 2022 Dec;245:109153. doi: 10.1016/j.clim.2022.109153. Epub 2022 Oct 
      17.